DE60237637D1 - Thiadiazolinderivate zur Krebsbehandlung - Google Patents

Thiadiazolinderivate zur Krebsbehandlung

Info

Publication number
DE60237637D1
DE60237637D1 DE60237637T DE60237637T DE60237637D1 DE 60237637 D1 DE60237637 D1 DE 60237637D1 DE 60237637 T DE60237637 T DE 60237637T DE 60237637 T DE60237637 T DE 60237637T DE 60237637 D1 DE60237637 D1 DE 60237637D1
Authority
DE
Germany
Prior art keywords
substituted
unsubstituted
cancer treatment
unsubstituted lower
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237637T
Other languages
English (en)
Inventor
Chikara Murakata
Kazuhiko Kato
Yoshihisa Ohta
Ryuichiro Nakai
Yoshinori Yamashita
Takeshi Takahashi
Tomohisa Nakano
Yoji Ino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Kyowa Kirin Co Ltd
Original Assignee
Fujifilm Corp
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp, Kyowa Hakko Kirin Co Ltd filed Critical Fujifilm Corp
Application granted granted Critical
Publication of DE60237637D1 publication Critical patent/DE60237637D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60237637T 2001-12-11 2002-12-11 Thiadiazolinderivate zur Krebsbehandlung Expired - Lifetime DE60237637D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001377456 2001-12-11
JP2002237399 2002-08-16
PCT/JP2002/012961 WO2003051854A1 (en) 2001-12-11 2002-12-11 Thiadiazoline derivative

Publications (1)

Publication Number Publication Date
DE60237637D1 true DE60237637D1 (de) 2010-10-21

Family

ID=26624996

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237637T Expired - Lifetime DE60237637D1 (de) 2001-12-11 2002-12-11 Thiadiazolinderivate zur Krebsbehandlung

Country Status (16)

Country Link
US (4) US7425636B2 (de)
EP (2) EP1454903B9 (de)
JP (1) JP4272994B2 (de)
KR (1) KR100915287B1 (de)
CN (1) CN100484928C (de)
AT (2) ATE480527T1 (de)
AU (1) AU2002354465B2 (de)
CA (1) CA2469801C (de)
CY (2) CY1112899T1 (de)
DE (1) DE60237637D1 (de)
DK (2) DK1847534T3 (de)
ES (1) ES2350642T3 (de)
HK (1) HK1107814A1 (de)
PT (2) PT1454903E (de)
SI (2) SI1454903T1 (de)
WO (1) WO2003051854A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100915287B1 (ko) 2001-12-11 2009-09-03 교와 핫꼬 기린 가부시키가이샤 티아디아졸린 유도체
AU2004230799B2 (en) 2003-04-18 2010-03-18 Fujifilm Corporation Mitotic kinesin inhibitor
EP1632484A4 (de) * 2003-06-10 2008-09-03 Kyowa Hakko Kogyo Kk Thiadiazolinderivat
JPWO2004111023A1 (ja) * 2003-06-10 2006-07-27 協和醗酵工業株式会社 チアジアゾリン−１−オキシド誘導体
EP1671957A4 (de) * 2003-10-10 2007-03-14 Thiadiazolinderivate
JPWO2005061707A1 (ja) * 2003-12-24 2007-07-12 協和醗酵工業株式会社 癌細胞のＥｇ５阻害剤に対する感受性を判定する方法
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CN101193877A (zh) * 2005-03-22 2008-06-04 协和发酵工业株式会社 造血系统肿瘤治疗剂
TW200714593A (en) * 2005-03-22 2007-04-16 Kyowa Hakko Kogyo Kk Agent for treatment of solid tumor
UA95907C2 (en) * 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
EP1908755A4 (de) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd Therapeutisches mittel gegen restenose
DE102005055354A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
EP2081918A2 (de) * 2006-10-03 2009-07-29 Array Biopharma, Inc. Inhibitoren von mitotischem kinesin und verfahren zu deren anwendung
AU2008275258A1 (en) 2007-07-12 2009-01-15 Eli Lilly And Company Stable formulations of thiadiazole derivatiive
CA2702922C (en) * 2007-10-19 2018-01-16 Schering Corporation Spiro-condensed 1,3,4-thiadiazole derivatives for inhibiting ksp kinesin activity

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE244989C (de)
US4246225A (en) * 1978-05-25 1981-01-20 Owens-Illinois, Inc. Method for forming tubular plastic articles
US4346225A (en) * 1981-06-15 1982-08-24 Eli Lilly And Company Herbicidal 2-methylamino thiadiazolines
US4338449A (en) * 1981-06-15 1982-07-06 Eli Lilly And Company Herbicidal thiadiazolines
US4699913A (en) 1985-06-28 1987-10-13 Ciba-Geigy Corporation Substituted 4,5-dihydro-1,3,4-thiadiazoles useful as insecticides
EP0217519B1 (de) * 1985-08-31 1992-02-05 FISONS plc 5-gliedrige heterocyclische Angiotensin-Umwandlungsenzym-Inhibitoren
DD243930A1 (de) 1985-12-04 1987-03-18 Akad Wissenschaften Ddr Verfahren zur herstellung von neuen 5,5-disubstituierten 4-carbamoyl-4,5-dihydro-1,3,4-thiadiazol-2-yl-harnstoffen
AU4288293A (en) * 1992-04-27 1993-11-29 E.I. Du Pont De Nemours And Company Fungicidal 1,3,4-oxadiazines and 1,3,4-thiadiazines
JP2798005B2 (ja) 1994-05-19 1998-09-17 三菱化学株式会社 平滑筋細胞増殖に起因する疾患の治療・予防剤
ATE157871T1 (de) 1994-05-19 1997-09-15 Mitsubishi Chem Corp Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
US5814647A (en) * 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
US6235762B1 (en) * 1998-11-23 2001-05-22 American Cyanamid Company 2-aryl-Δ2-1,3,4-(oxa and thia)diazoline insecticidal and acaricidal agents
JP2000159756A (ja) 1998-11-23 2000-06-13 American Cyanamid Co ２―アリ―ル―δ２―１，３，４―（オキサおよびチア）ジアゾリン殺虫および殺ダニ剤
JP2000204077A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
CZ20012528A3 (cs) * 1999-01-13 2002-06-12 Warner-Lambert Company 1-Heterocyklicky substituované diarylaminy, farmaceutické kompozice na jejich bázi a způsoby léčení
JP2000229959A (ja) * 1999-02-04 2000-08-22 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
DE60028227T2 (de) 1999-10-27 2007-03-29 Cytokinetics, Inc., South San Francisco Chinazolinone benutzende verfahren und zusammenstellungen
US6617115B1 (en) * 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
AU2001234741A1 (en) * 2000-02-04 2001-08-14 Biogen, Inc. Integrin antagonists
US6310716B1 (en) 2000-08-18 2001-10-30 Corning Incorporated Amplifier system with a discrete Raman fiber amplifier module
US6992082B2 (en) * 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
EP1351671A1 (de) 2001-01-19 2003-10-15 Cytokinetics, Inc. Triphenylmethanderivate als kinesinhemmer
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6809102B2 (en) * 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
CA2442455A1 (en) * 2001-03-29 2002-10-10 Deborah L. Roussell A method of treating proliferative diseases using eg5 inhibitors
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
KR100915287B1 (ko) 2001-12-11 2009-09-03 교와 핫꼬 기린 가부시키가이샤 티아디아졸린 유도체
US6561831B1 (en) 2001-12-27 2003-05-13 Hon Hai Precision Ind. Co., Ltd. Housing of socket connector and conductive terminal thereof
AU2003249597B2 (en) * 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
AU2003299517A1 (en) 2002-05-23 2004-05-25 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2004230799B2 (en) 2003-04-18 2010-03-18 Fujifilm Corporation Mitotic kinesin inhibitor
JPWO2004111023A1 (ja) 2003-06-10 2006-07-27 協和醗酵工業株式会社 チアジアゾリン−１−オキシド誘導体
EP1632484A4 (de) 2003-06-10 2008-09-03 Kyowa Hakko Kogyo Kk Thiadiazolinderivat
EP1671957A4 (de) 2003-10-10 2007-03-14 Thiadiazolinderivate
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
CN101193877A (zh) 2005-03-22 2008-06-04 协和发酵工业株式会社 造血系统肿瘤治疗剂
TW200714593A (en) 2005-03-22 2007-04-16 Kyowa Hakko Kogyo Kk Agent for treatment of solid tumor
EP1908755A4 (de) 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd Therapeutisches mittel gegen restenose

Also Published As

Publication number Publication date
EP1454903B1 (de) 2010-09-08
EP1847534A2 (de) 2007-10-24
EP1847534B1 (de) 2011-06-22
CA2469801C (en) 2011-06-21
EP1847534B9 (de) 2012-03-21
ATE513821T1 (de) 2011-07-15
EP1454903B9 (de) 2011-10-05
SI1847534T1 (sl) 2011-10-28
KR20040072649A (ko) 2004-08-18
AU2002354465A1 (en) 2003-06-30
SI1454903T1 (sl) 2010-12-31
CN100484928C (zh) 2009-05-06
JPWO2003051854A1 (ja) 2005-04-28
US20080207706A1 (en) 2008-08-28
DK1454903T3 (da) 2010-11-22
US7425636B2 (en) 2008-09-16
US7759371B2 (en) 2010-07-20
ATE480527T1 (de) 2010-09-15
KR100915287B1 (ko) 2009-09-03
JP4272994B2 (ja) 2009-06-03
EP1454903A1 (de) 2004-09-08
WO2003051854A1 (en) 2003-06-26
CY1112899T1 (el) 2016-04-13
CN1617864A (zh) 2005-05-18
PT1847534E (pt) 2011-08-01
DK1847534T3 (da) 2011-08-29
CA2469801A1 (en) 2003-06-26
EP1454903A4 (de) 2005-12-21
US20060074113A1 (en) 2006-04-06
PT1454903E (pt) 2010-11-09
US20070213380A1 (en) 2007-09-13
US20100240716A1 (en) 2010-09-23
US7902234B2 (en) 2011-03-08
HK1107814A1 (en) 2008-04-18
EP1847534A3 (de) 2008-09-24
AU2002354465B2 (en) 2008-11-20
CY1111816T1 (el) 2015-10-07
ES2350642T3 (es) 2011-01-25

Similar Documents

Publication Publication Date Title
CY1111816T1 (el) Παραγωγο θειαδιαζολινης για την θεραπεια του καρκινου
NL300927I1 (nl) tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
NO20012617L (no) Kinolin- og kinzolinderivater
HK1158637A1 (en) Mitotic kinesin inhibitor m
EP1902716A4 (de) Prophylaktisches und/oder therapeutisches mittel für motorische störungen
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
NO20014925L (no) Farmasöytiske forbindelser
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
DE60027144D1 (de) Hydroxamsäure-derivate
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
EP1671957A4 (de) Thiadiazolinderivate
ATE223411T1 (de) 1-methylcarbapenem-derivate
ATE239741T1 (de) Derivate der phosphonsäure zur inhibierung von carboxypeptidase b
ATE283840T1 (de) Chondrogonese promotoren und indolin-2-on derivate
DE69930383D1 (de) Naphthimidobenzamid-derivate
DK1433480T3 (da) Lægemiddel indeholdende pyrimidin-derivat
ATE552003T1 (de) Chinoxalinderivate
EP1234576A4 (de) Heilmittel gegen essstörungen
MX9704976A (es) Derivados de 1,2,3-benzotiadiazol.